Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2017 from OUS - Department of Urology

13 publications found

Axcrona K, Nilsson R, Brennhovd B, Sørebø Ø, Fosså SD, Dahl AA (2017)
Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations
BMC Urol, 17 (1), 111
DOI 10.1186/s12894-017-0302-7, PubMed 29197360

Bilir B, Sharma NV, Lee J, Hammarstrom B, Svindland A, Kucuk O, Moreno CS (2017)
Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer
Int J Oncol, 51 (1), 223-234
DOI 10.3892/ijo.2017.4017, PubMed 28560383

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
DOI 10.1038/bjc.2017.346, PubMed 28972967

Cai T, Koves B, Johansen TE (2017)
Asymptomatic bacteriuria, to screen or not to screen - and when to treat?
Curr Opin Urol, 27 (2), 107-111
DOI 10.1097/MOU.0000000000000368, PubMed 27906777

Cai T, Tamanini I, Kulchavenya E, Perepanova T, Köves B, Wagenlehner FM, Tandogdu Z, Bonkat G, Bartoletti R, Bjerklund Johansen TE (2017)
The role of nutraceuticals and phytotherapy in the management of urinary tract infections: What we need to know?
Arch Ital Urol Androl, 89 (1), 1-6
DOI 10.4081/aiua.2017.1.1, PubMed 28403585

Idland AV, Wyller TB, Støen R, Eri LM, Frihagen F, Ræder J, Chaudhry FA, Hansson O, Zetterberg H, Blennow K, Bogdanovic N, Brækhus A, Watne LO (2017)
Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium
J Alzheimers Dis, 55 (1), 371-379
DOI 10.3233/JAD-160461, PubMed 27662296

Li X, Grigalavicius M, Li Y, Li X, Zhong Y, Huang R, Yu D, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
MtDNA depletion influences the transition of CD44 subtypes in human prostate cancer DU145 cells
Tumour Biol, 39 (8), 1010428317713671
DOI 10.1177/1010428317713671, PubMed 28789597

Li X, Han G, Li X, Kan Q, Fan Z, Li Y, Ji Y, Zhao J, Zhang M, Grigalavicius M, Berge V, Goscinski MA, Nesland JM, Suo Z (2017)
Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells
Oncotarget, 8 (28), 46363-46380
DOI 10.18632/oncotarget.18199, PubMed 28624784

Li X, Lu J, Kan Q, Li X, Fan Q, Li Y, Huang R, Slipicevic A, Dong HP, Eide L, Wang J, Zhang H, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
Sci Rep, 7 (1), 5081
DOI 10.1038/s41598-017-05086-6, PubMed 28698547

McDonald M, Kameh D, Johnson ME, Johansen TEB, Albala D, Mouraviev V (2017)
A Head-to-Head Comparative Phase II Study of Standard Urine Culture and Sensitivity Versus DNA Next-generation Sequencing Testing for Urinary Tract Infections
Rev Urol, 19 (4), 213-220
DOI 10.3909/riu0780, PubMed 29472825

Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, Sandvig K, Linē A, Llorente A (2017)
Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes
Mol Cancer, 16 (1), 156
DOI 10.1186/s12943-017-0726-4, PubMed 28982366

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW et al. (2017)
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology
Eur Urol, 72 (4), 509-518
DOI 10.1016/j.eururo.2017.03.027, PubMed 28408174

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD (2017)
Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway
Urology, 110, 140-147
DOI 10.1016/j.urology.2017.07.048, PubMed 28823634

 
Page visits: 409879